Logo Université Laval Logo Université Laval
International Chair on Cardiometabolic Risk
My Healthy Waist

Documentation centre

1933-1944 of 2541 results
Page 162 of 212
Key Publications March 6, 2017

Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force.

JAMA. 2016;316:2008-2024

Chou R, Dana T, Blazina I, Daeges M, Jeanne TL
Cardiovascular Disease Lipids/Lipoproteins Prevention
Key Publications March 3, 2017

Interpretation and use of another statin guideline.

JAMA. 2016;316:1977-1979

Greenland P, Bonow RO
Cardiovascular Disease Lipids/Lipoproteins Prevention
Key Publications March 3, 2017

Statins for primary prevention: The debate is intense, but the data are weak.

JAMA. 2016;316:1979-1981

Redberg RF, Katz MH
Cardiovascular Disease Lipids/Lipoproteins Prevention
Key Publications March 3, 2017

Evolving approaches for statins in primary prevention: Progress, but questions remain.

JAMA. 2016;316:1981-1983

Navar AM, Peterson ED
Cardiovascular Disease Lipids/Lipoproteins Prevention
Key Publications March 2, 2017

Statins for primary prevention in older adults: Uncertainty and the need for more evidence.

JAMA. 2016;316:1971-1972

Gurwitz JH, Go AS, Fortmann SP
Age Cardiovascular Disease Lipids/Lipoproteins
Key Publications March 2, 2017

Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and the future of LDL-C Lowering.

JAMA. 2016;316:1967-1968

Rodriguez F, Harrington RA
Cardiovascular Disease Clinical Trials Lipids/Lipoproteins
Key Publications March 2, 2017

What to believe and do about statin-associated adverse effects.

JAMA. 2016;316:1969-1970

Thompson PD
Cardiovascular Disease Clinical Trials Lipids/Lipoproteins
Expert Opinions March 1, 2017

Why is poor cardiorespiratory fitness such a powerful predictor of various clinical outcomes?

Jonathan Myers, PhD, FACC, FACSM, FAACVPR, FAHA, Health Research Scientist, VA Palo Alto Health Care System; Clinical Professor of Medicine, Stanford University, Palo Alto, CA, USA
Cardiometabolic Risk Cardiovascular Disease Physical Activity/Exercise
Key Publications March 1, 2017

Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes

Diabetologia. 2016;59:2603-2612

van der Leeuw J, Visseren FL, Woodward M, van der Graaf Y, Grobbee DE, Harrap S, Heller S, Mancia G, Marre M, Poulter N, Zoungas S, Chalmers J
Cardiovascular Disease Clinical Trials Diabetes
Key Publications February 28, 2017

Association between plasma lipoprotein levels and bioprosthetic valve structural degeneration.

Heart. 2016;102:1915-1921

Nsaibia MJ, Mahmut A, Mahjoub H, Dahou A, Bouchareb R, Boulanger MC, Després JP, Bossé Y, Arsenault BJ, Larose E, Pibarot P, Mathieu P
Cardiovascular Disease Inflammation Lipids/Lipoproteins
Key Publications February 27, 2017

Diabetes: Steno-2 - a small study with a big heart.

Nat Rev Endocrinol. 2016:692-694

Bajaj H, Zinman B
Cardiovascular Disease Clinical Trials Diabetes
Key Publications February 27, 2017

Cross-sectional analysis of deprivation and ideal cardiovascular health in the Paris Prospective Study 3.

Heart. 2016;102:1890-1897

Empana JP, Perier MC, Singh-Manoux A, Gaye B, Thomas F, Prugger C, Plichart M, Wiernik E, Guibout C, Lemogne C, Pannier B, Boutouyrie P, Jouven X
Cardiovascular Disease Prevention Sex Differences
of 212